Description: <b>Selenium NanoParticles</b><br>
<pre>
| Category | Role in cancer |
| -------------------------------- | ----------------------------------------------------------------------------------------------- |
| Sodium Selenium (selenite) | Direct cytotoxic redox poison |
| Selenium (organic / nutritional) | **Redox buffer & immune modulator** (generally *anti-therapy* when oxidative stress is desired) |
| SeNPs | Tunable redox-signaling anticancer platform |
</pre>
The introduction of borneol led to a significant reduction in the size of selenium nanoparticles (SeNPs), as documented in the study (Prabhakaret et al., 2013).<br>
In the chemical synthesis of selenium nanoparticles, a precursor such as sodium selenite (Na₂SeO₃) is dissolved in water to form a homogenous solution. A reducing agent, like ascorbic acid or sodium borohydride (NaBH₄), is then added to the solution. The reducing agent donates electrons to the selenium ions (SeO32−SeO32), reducing them to elemental selenium (Se0Se^0). This reduction process leads to the nucleation of selenium atoms, which subsequently grow into nanoparticles through controlled aggregation. <br>
<br>
<a href="https://nestronics.ca/dbx/tbResEdit.php?rid=4440">Se NPs might be hepatoprotective.</a><br>
<a href="https://nestronics.ca/dbx/tbResList.php?qv=149&tsv=1171&wNotes=on">(chemoprotective)</a>
<a href="https://nestronics.ca/dbx/tbResList.php?qv=149&tsv=1185&wNotes=on">(radioprotective)</a>
<a href="https://nestronics.ca/dbx/tbResList.php?qv=149&tsv=1107&wNotes=on">(radiosensitizer)</a><br>
<br>
<pre>
Selenium nanoparticles (SeNPs) are a biocompatible, less-toxic,
and more controllable form of selenium compared to inorganic salts (like sodium selenite).
Major SeNPs hepatoprotective mechanisms
Mechanism Description Key markers affected
1. Antioxidant activity SeNPs boost antioxidant enzyme ↓ ROS, ↓ MDA, ↑ GSH, ↑ GPx
systems (GPx, SOD, CAT) and scavenge
ROS directly.
2. Anti-inflammatory effect Downregulate NF-κB, TNF-α, ↓ TNF-α, ↓ IL-1β, ↓ IL-6
IL-6, and COX-2 pathways.
3. Anti-apoptotic action Balance between Bcl-2/Bax and reduce ↑ Bcl-2, ↓ Bax, ↓ Caspase-3
caspase-3 activation in hepatocytes.
4. Metal/toxin chelation SeNPs can bind or transform toxic ↓ liver metal accumulation
metals (Cd²⁺, Hg²⁺, As³⁺)
into less harmful complexes.
5. Mitochondrial protection Maintain membrane potential, Preserved ΔΨm, ↑ ATP
prevent mitochondrial ROS burst,
and ATP loss.
6. Regeneration support Stimulate hepatocyte proliferation ↑ PCNA, improved histology
and repair via redox signaling
and selenoproteins.
Comparison: SeNPs vs. Sodium Selenite
Property SeNPs Sodium Selenite
Toxicity Low Moderate–high
Bioavailability Controlled, often slow- Rapid, less controllable
release
ROS balance Adaptive, mild antioxidant Can flip to pro-oxidant easily
Safety margin Wide Narrow
Hepatoprotection Strong, sustained Protective at low dose,
toxic at high dose
</pre>
Form of SeNPs matter:<br>
1. Core composition / capping agent: SeNPs can be stabilized with polysaccharides, proteins, or small molecules. Some stabilizers may interact with cellular redox systems differently—e.g., a protein-capped SeNP may have slower release and less ROS generation, whereas a bare SeNP might induce stronger ROS in cancer cells.<br>
2. Particle size: Smaller SeNPs (<50 nm) tend to generate more ROS and may enhance anticancer activity, but could theoretically interfere with ROS-dependent chemo if administered simultaneously. Larger SeNPs are slower-acting and may be safer alongside chemo.<br>
3. Surface charge / coating: Positively charged or functionalized SeNPs can preferentially enter tumor cells, whereas neutral or negatively charged forms may distribute more evenly. This affects both selective cytotoxicity and interaction with normal cells.<br>
<br>
"30 mg of Na2SeO3.5H2O was added to 90 mL of Milli-Q water.
Ascorbic acid (10 mL, 56.7 mM) was added dropwise to sodium selenite solution with vigorous stirring.
10 µL of polysorbate were added after each 2 ml of ascorbic acid.
Selenium nanoparticles were formed after the addition of ascorbic acid.
This can be visualized by a color change of the reactant solution from clear white to clear red.
All solutions were made in a sterile environment by using a sterile cabinet and double distilled water."<br>
<br>
SeNPs Cancer relevant pathways
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway (direction)</th>
<th>Notes (key mechanistic readout)</th>
<th>Ref</th>
</tr>
<tr>
<td>1</td>
<td>Redox stress / ROS ↑</td>
<td>SeNPs commonly elevate intracellular ROS in cancer cells (often upstream of downstream apoptosis/autophagy signaling).</td>
<td><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8582357/">(ref)</a></td>
</tr>
<tr>
<td>2</td>
<td>DNA damage / DDR ↑</td>
<td>ROS-linked DNA damage response reported in anti-angiogenic/cancer models (e.g., DNA damage as part of the cytotoxic cascade).</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/26961468/">(ref)</a></td>
</tr>
<tr>
<td>3</td>
<td>PI3K → Akt → mTOR ↓</td>
<td>Frequently reported as inhibited (or functionally downshifted), aligning with reduced survival signaling and increased stress-death programs.</td>
<td><a href="https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2023.1116051/full">(ref)</a></td>
</tr>
<tr>
<td>4</td>
<td>Mitochondrial integrity (ΔΨm) ↓</td>
<td>Mitochondrial membrane potential loss is a recurring early event (mitochondria-centered cytotoxicity).</td>
<td><a href="https://royalsocietypublishing.org/doi/10.1098/rsos.180509">(ref)</a></td>
</tr>
<tr>
<td>5</td>
<td>Intrinsic apoptosis (caspase cascade) ↑</td>
<td>Activation of caspase-mediated apoptosis (e.g., caspase-3 activation) commonly follows mitochondrial disruption.</td>
<td><a href="https://royalsocietypublishing.org/doi/10.1098/rsos.180509">(ref)</a></td>
</tr>
<tr>
<td>6</td>
<td>Stress MAPK (p38) ↑</td>
<td>p38 signaling is reported as engaged in ROS-associated SeNP cytotoxicity programs (context: apoptosis signaling).</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/30564384/">(ref)</a></td>
</tr>
<tr>
<td>7</td>
<td>p53 program ↑</td>
<td>p53 pathway activation/“reactivation” can be amplified in SeNP-based constructs (p53 target genes up; apoptosis up).</td>
<td><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12615484/">(ref)</a></td>
</tr>
<tr>
<td>8</td>
<td>Autophagy regulation ↑ (often pro-death or dysregulated)</td>
<td>Functionalized SeNPs can drive autophagy as a major action mode in colorectal cancer models (often intertwined with cytotoxicity).</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/30091749/">(ref)</a></td>
</tr>
<tr>
<td>9</td>
<td>Angiogenesis (VEGF → VEGFR2 → ERK/Akt) ↓</td>
<td>Anti-angiogenic SeNP designs suppress VEGF-driven signaling and tube formation in endothelial/tumor angiogenesis models.</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/26961468/">(ref)</a></td>
</tr>
<tr>
<td>10</td>
<td>NF-κB signaling ↓</td>
<td>NF-κB activation markers (e.g., p-p65 / p-IκBα) can be reduced by decorated SeNPs in inflammatory signaling models relevant to tumor-promoting inflammation.</td>
<td><a href="https://link.springer.com/article/10.1186/s12951-017-0252-y">(ref)</a></td>
</tr>
<tr>
<td>11</td>
<td>Androgen receptor axis (AR transcriptional activity) ↓</td>
<td>Reported in prostate cancer context: AR downregulation/disruption via Akt/Mdm2/AR-linked apoptosis framework.</td>
<td><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3431821/">(ref)</a></td>
</tr>
<tr>
<td>12</td>
<td>Ferroptosis ↑ (Nrf2/HO-1/SLC7A11/GCLC/GPX4 ↓)</td>
<td>Some decorated SeNPs are explicitly reported to induce ferroptosis, including downregulation of System Xc−/GSH/GPX4-axis proteins and iron-homeostasis shifts.</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/39701247/">(ref)</a></td>
</tr>
</table>
<br>
<br>
<h2>Selenium Nanoparticles (SeNPs) and Alzheimer’s Disease (AD)</h2>
<p><b>Overview:</b> Selenium nanoparticles (SeNPs) are being investigated in Alzheimer’s disease primarily as a <b>multifunctional neuroprotective nanoplatform</b> rather than as a conventional nutrient supplement. In AD-oriented studies, SeNPs are used for one or more of the following: (1) direct inhibition of amyloid-β (Aβ) aggregation, (2) reduction of oxidative stress, (3) lowering of neuroinflammation, (4) improved blood-brain barrier (BBB) transport via targeting ligands, and/or (5) delivery or stabilization of partner compounds with poor brain availability. Current support is mainly from cell studies and rodent AD models, so the evidence is still <b>experimental/preclinical</b>, not established clinical therapy.</p>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Direction in AD Context</th>
<th>Proposed Relevance</th>
<th>Confidence</th>
</tr>
<tr>
<td>1</td>
<td>Aβ aggregation / fibrillation</td>
<td>↓</td>
<td>Core and most repeated AD-SeNP mechanism; many formulations are designed to bind Aβ and reduce fibril formation / toxicity.</td>
<td>High (preclinical)</td>
</tr>
<tr>
<td>2</td>
<td>Oxidative stress / ROS burden</td>
<td>↓</td>
<td>SeNPs often act as antioxidant nanoagents and/or improve delivery of antioxidant polyphenols.</td>
<td>High (preclinical)</td>
</tr>
<tr>
<td>3</td>
<td>Neuroinflammation</td>
<td>↓</td>
<td>Reduced inflammatory cytokines and inflammasome-linked signaling are reported in several SeNP formulations.</td>
<td>Moderate-High</td>
</tr>
<tr>
<td>4</td>
<td>Tau phosphorylation / tau-linked injury</td>
<td>↓</td>
<td>Some formulations report reduced tau phosphorylation or downstream tau-associated neurotoxicity.</td>
<td>Moderate</td>
</tr>
<tr>
<td>5</td>
<td>BBB penetration / brain delivery</td>
<td>↑</td>
<td>Frequently engineered with peptides or surface modifications to improve CNS targeting.</td>
<td>Moderate-High</td>
</tr>
<tr>
<td>6</td>
<td>Neuronal survival / cognition</td>
<td>↑</td>
<td>Animal models often report improved memory performance and reduced histologic damage.</td>
<td>Moderate</td>
</tr>
<tr>
<td>7</td>
<td>Microglial / metabolic dysregulation</td>
<td>↓</td>
<td>Newer studies suggest effects on microglia, gut-metabolic inflammation, or glucolipid-associated AD aggravation.</td>
<td>Moderate</td>
</tr>
</table>
<h3>Mechanistic Summary</h3>
<ul>
<li><b>Aβ-directed action:</b> A major rationale for SeNP use in AD is their reported ability to interact with amyloid species and suppress Aβ aggregation/fibrillation.</li>
<li><b>Redox modulation:</b> SeNPs are commonly positioned as ROS-lowering / antioxidant nanomaterials, which is relevant because oxidative injury is a major contributor to neuronal dysfunction in AD.</li>
<li><b>Anti-inflammatory effects:</b> Several SeNP systems reduce neuroinflammatory signaling, including cytokine-linked and inflammasome-linked injury pathways.</li>
<li><b>Carrier function:</b> SeNPs are often used as a delivery/stabilization platform for poorly bioavailable neuroprotective compounds such as chlorogenic acid, resveratrol, curcumin, EGCG, dihydromyricetin, and metformin-derived combination systems.</li>
<li><b>Targeting function:</b> Surface ligands such as Tet-1, B6, TGN, LPFFD, sialic acid, chondroitin sulfate, or chitosan-related constructs are used to improve BBB transport, Aβ targeting, or stability.</li>
</ul>
<h3>Overall Modulation Direction in AD</h3>
<ul>
<li>Aβ aggregation: <b>decreased</b></li>
<li>ROS / oxidative stress: <b>decreased</b></li>
<li>Neuroinflammation: <b>decreased</b></li>
<li>Tau pathology: <b>often decreased</b> (formulation-dependent)</li>
<li>Brain delivery / retention of partner compounds: <b>increased</b></li>
<li>Cognitive performance in animal models: <b>improved</b></li>
</ul>
<h3>Evidence Level</h3>
<p><b>Preclinical.</b> The AD literature for SeNPs is mainly cell culture and rodent-model work. Formulation-specific effects are important; benefits shown for one coated or ligand-targeted SeNP system should not automatically be generalized to all selenium nanoparticles or to ordinary selenium supplementation.</p>
<h3>Notes / Interpretation</h3>
<ul>
<li>SeNPs in AD are best viewed as a <b>platform technology</b>: anti-amyloid + antioxidant + delivery-enhancing.</li>
<li>The strongest and most repeated theme is <b>Aβ aggregation inhibition combined with ROS reduction</b>.</li>
<li>Because many studies use specialized coatings/ligands, the active effect may come from the <b>combined nanoformulation</b>, not selenium alone.</li>
<li>This should <b>not</b> be treated as equivalent to standard oral selenium supplements.</li>
</ul>
<h3>SeNP-Associated Products / Components Used in AD-Oriented Nanoformulations</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Product / Component</th>
<th>Role with SeNPs</th>
<th>AD-Relevant Purpose</th>
<th>Notes</th>
</tr>
<tr>
<td><a href="https://nestronics.ca/dbx/tbResList.php?qv=391&qv2=59">Chlorogenic acid (CGA)</a></td>
<td>Cargo / functional partner</td>
<td>Antioxidant, anti-Aβ support, improved activity at lower dose</td>
<td>Reported in brain-targeted flower-like selenium nanocluster systems.</td>
</tr>
<tr>
<td>Resveratrol</td>
<td>Cargo / functionalized partner</td>
<td>Anti-Aβ, antioxidant, anti-inflammatory; improved bioavailability</td>
<td>One of the most repeatedly reported SeNP combinations in AD models.</td>
</tr>
<tr>
<td>Epigallocatechin gallate (EGCG)</td>
<td>Stabilizer / functional partner</td>
<td>Anti-aggregation and antioxidant support</td>
<td>Used with Tet-1-coated SeNPs in an early AD-targeting formulation.</td>
</tr>
<tr>
<td>Curcumin</td>
<td>Cargo / selenium nanoformulation partner</td>
<td>Neuroprotection, antioxidant support, potential anti-amyloid benefit</td>
<td>Reported in curcumin-selenium nanoformulations for AD-type models.</td>
</tr>
<tr>
<td>Dihydromyricetin (DMY)</td>
<td>Cargo</td>
<td>Anti-inflammatory / anti-amyloid / NLRP3-linked effects</td>
<td>Reported in Tg-CS/DMY@SeNPs systems.</td>
</tr>
<tr>
<td>Metformin</td>
<td>Cargo</td>
<td>Microglia / neuroinflammation / ROS modulation</td>
<td>Reported in newer mesoporous nanoselenium delivery systems.</td>
</tr>
<tr>
<td>Chitosan (CS)</td>
<td>Coating / carrier matrix</td>
<td>Stability, delivery, BBB-associated formulation support</td>
<td>Often paired with resveratrol or DMY formulations.</td>
</tr>
<tr>
<td>Chondroitin sulfate (CS)</td>
<td>Surface modifier / carrier component</td>
<td>Targeting and neuroprotective formulation enhancement</td>
<td>Used in AD mouse models with selenium-based nanosystems.</td>
</tr>
<tr>
<td>Tet-1 peptide</td>
<td>Targeting ligand</td>
<td>Neuronal targeting / BBB-related delivery improvement</td>
<td>Commonly used as a targeting coat rather than therapeutic cargo.</td>
</tr>
<tr>
<td>B6 peptide</td>
<td>BBB-targeting ligand</td>
<td>Improved brain penetration</td>
<td>Used with SA-modified SeNP systems.</td>
</tr>
<tr>
<td>TGN peptide</td>
<td>BBB-targeting ligand</td>
<td>Improved CNS delivery</td>
<td>Used in several AD-focused SeNP designs.</td>
</tr>
<tr>
<td>LPFFD peptide</td>
<td>Aβ-targeting ligand</td>
<td>Direct amyloid-binding / anti-aggregation support</td>
<td>Often combined with TGN for dual-function SeNPs.</td>
</tr>
<tr>
<td>Sialic acid (SA)</td>
<td>Surface modifier</td>
<td>Brain-targeting / biomimetic delivery enhancement</td>
<td>Used in peptide-assisted BBB-crossing SeNP systems.</td>
</tr>
</table>
<h3>Bottom Line</h3>
<p>For AD, selenium nanoparticles appear most relevant as a <b>multi-target anti-amyloid / antioxidant nanocarrier platform</b>. Their strongest support is for reducing Aβ aggregation and oxidative-neuroinflammatory injury while improving delivery of partner neuroprotective compounds. At present, this is a <b>research-stage strategy</b>, not a validated clinical AD treatment.</p>